title: Fragment screening to predict druggability (ligandability) and lead discovery success.
authors.affiliation: Discovery-Enabling Capabilities and Sciences, AstraZeneca R&D, S-43183 Mölndal, Sweden. Fredrik.Edfeldt@astrazeneca.com
authors.forename: Fredrik N B
authors.initials: FN
authors.lastname: Edfeldt
authors.forename: Rutger H A
authors.initials: RH
authors.lastname: Folmer
authors.forename: Alexander L
authors.initials: AL
authors.lastname: Breeze
mesh_terms: D055808:Drug Discovery / Q000379:methods*; D004353:Drug Evaluation, Preclinical; D004345:Drug Industry; D057166:High-Throughput Screening Assays; D006801:Humans; D008024:Ligands; D058990:Molecular Targeted Therapy; D010446:Peptide Fragments / Q000378:metabolism
chemical_list: D008024:Ligands; D010446:Peptide Fragments